The value and limitations of new oral anticoagulant plasma level assessments

Area of Science:

• Pharmacology
• Cardiology
• Internal Medicine

Background:

• New oral anticoagulants (NOACs) were developed to simplify anticoagulation therapy.
• Fixed doses were chosen based on early trials and modeling, aiming to avoid therapeutic drug monitoring.
• Large clinical trials demonstrated NOACs to be as effective and safe as warfarin with monitoring.

Purpose of the Study:

• To review the potential clinical scenarios where measuring NOAC plasma levels may be beneficial.
• To discuss the limitations and practical aspects of NOAC plasma concentration measurement.
• To provide guidance on the utility of NOAC level testing.

Main Methods:

• Review of phase I, II, and III clinical trial data.
• Analysis of pharmacokinetic and pharmacodynamic modeling studies.
• Evaluation of real-world evidence on NOAC use.
• Discussion of clinical scenarios and practical implementation of NOAC level measurement.

Main Results:

• Fixed-dose NOACs are effective and safe without routine monitoring in large patient populations.
• Real-world data support the safety and efficacy of fixed-dose NOACs across diverse patients.
• NOAC plasma level measurement is not routinely required but can offer valuable information in specific situations.

Conclusions:

• Routine therapeutic drug monitoring is not necessary for NOACs.
• Measuring NOAC plasma concentrations can be useful in select clinical circumstances, such as overdose or suspected non-adherence.
• Further research and clear guidelines are needed for the practical implementation of NOAC level testing.